Quinazoline-Pyrazole Hybrids as DHFR Inhibitors in Cancer
Quinazoline-Pyrazole Hybrids as DHFR Inhibitors in Cancer
Created using ChatSlide
This study investigates the potential of quinazoline-pyrazole hybrid compounds as innovative therapeutic agents in lung cancer therapy, specifically targeting non-small cell lung cancer (NSCLC). Highlighting the significant role of dihydrofolate reductase (DHFR) in oncogenesis, the research integrates pharmacophore studies to synthesize and characterize these hybrid compounds. Utilizing cell lines H460 and A549, compound 1A-h exhibited significant antiproliferative activity, with promising...